Qiagen has published its financial results for the second quarter of 2012, during which it experienced a strong increase in sales.
The company's net sales rose by nine percent year on year to reach a total of $307.2 million (197.67 million pounds), with growth observed across all regions and customer classes.
Molecular diagnostics and applied testing product sales were noted as being particularly robust, while the firm was also able to expand through the acquisition of Cellestis, Ipsogen and AmniSure.